IRIDEX Corporation (IRIX)
NASDAQ: IRIX · Real-Time Price · USD
0.9746
+0.0356 (3.79%)
At close: Dec 11, 2025, 4:00 PM EST
0.9705
-0.0040 (-0.42%)
After-hours: Dec 11, 2025, 4:04 PM EST
IRIDEX Revenue
IRIDEX had revenue of $12.48M in the quarter ending September 27, 2025, with 7.80% growth. This brings the company's revenue in the last twelve months to $50.65M, up 4.58% year-over-year. In the year 2024, IRIDEX had annual revenue of $48.67M, down -6.17%.
Revenue (ttm)
$50.65M
Revenue Growth
+4.58%
P/S Ratio
0.31
Revenue / Employee
$544,591
Employees
93
Market Cap
16.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 28, 2024 | 48.67M | -3.20M | -6.17% |
| Dec 30, 2023 | 51.87M | -5.10M | -8.96% |
| Dec 31, 2022 | 56.97M | 3.07M | 5.69% |
| Jan 1, 2022 | 53.90M | 17.56M | 48.30% |
| Jan 2, 2021 | 36.35M | -7.10M | -16.34% |
| Dec 28, 2019 | 43.45M | 847.00K | 1.99% |
| Dec 29, 2018 | 42.60M | 1.01M | 2.42% |
| Dec 30, 2017 | 41.59M | -4.57M | -9.89% |
| Dec 31, 2016 | 46.16M | 4.40M | 10.54% |
| Jan 2, 2016 | 41.76M | -1.06M | -2.47% |
| Jan 3, 2015 | 42.81M | 4.54M | 11.86% |
| Dec 28, 2013 | 38.27M | 4.41M | 13.04% |
| Dec 29, 2012 | 33.86M | 700.00K | 2.11% |
| Dec 31, 2011 | 33.16M | 851.00K | 2.63% |
| Jan 1, 2011 | 32.31M | 1.28M | 4.11% |
| Jan 2, 2010 | 31.03M | -17.50M | -36.05% |
| Jan 3, 2009 | 48.53M | -7.00M | -12.61% |
| Dec 29, 2007 | 55.53M | 19.63M | 54.67% |
| Dec 30, 2006 | 35.90M | -1.13M | -3.04% |
| Dec 31, 2005 | 37.03M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IRIX News
- 12 hours ago - Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management - GlobeNewsWire
- 3 days ago - Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment - GlobeNewsWire
- 6 days ago - Iridex to Present at the Sidoti Year-End Virtual Investor Conference - GlobeNewsWire
- 4 weeks ago - IRIDEX Corporation (IRIX) Q3 2025 Earnings Call Prepared Remarks Transcript - Seeking Alpha
- 4 weeks ago - Iridex Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Iridex to Report Third Quarter 2025 Financial Results on November 11, 2025 - GlobeNewsWire
- 3 months ago - Iridex Corporation Receives Formal Notification of Nasdaq Listing Compliance - GlobeNewsWire
- 4 months ago - IRIDEX Corporation (IRIX) Q2 2025 Earnings Call Transcript - Seeking Alpha